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Abstract.
The concept of selective receptor modulators has been established for the nuclear steroid hormone receptors. Such selective modulators have been utilized therapeutically with great success in the treatment of cancer. However, this concept has not been examined with regard to the aryl hydrocarbon receptor (AHR) because of the latent toxicity commonly associated with AHR activation. AHR-mediated toxicity is primarily derived from AHR binding to its dioxin response element (DRE) and driving expression of CYP1 family members, which have the capacity to metabolize procarcinogens to genotoxic carcinogens. Recent evidence using a non-DRE binding AHR mutant has established the DREindependent suppression of inflammatory markers by the AHR. We wished to determine if such DREindependent repression with wild-type AHR could be dissociated from canonical DRE-dependent transactivation in a ligand-dependent manner and, in doing so, prove the concept of a selective AHR modulator (SAhRM). Here, we identify the SERM Way-169916 as a dually selective modulator, binding both ER and AHR. Inflammatory gene expression associated with the cytokine-inducible acute phase response (APR) e.g. SAA1 and CRP is diminished by Way-169916 in an AHR-dependent manner.
Furthermore, activation of AHR by Way-169916 fails to stimulate canonical DRE-driven AHR-mediated CYP1A1 expression, thus eliminating the potential for AHR-mediated genotoxic stress. Such antiinflammatory activity in the absence of DRE-mediated expression fulfills the major criteria of a SAhRM, which suggests that selective modulation of AHR is possible and renders the AHR a therapeutically viable drug target for the amelioration of inflammatory disease.
This article has not been copyedited and formatted. The final version may differ from this version. For many decades the ascribed function of the aryl hydrocarbon receptor (AHR) has been that of a xenobiotic sensor, modulating gene expression, principally P450 detoxifying enzymes, e.g. CYP1A1, in response to environmental ligands, e.g. dioxin. Such contaminants are products of the industrial age and fail to account for the evolutionary persistence of the AHR. Recently, a paradigm shift has occurred regarding AHR function. Whilst the detoxification role of AHR is not in doubt, the development of Ahr null and transgenic rodent models indicate physiological roles for AHR beyond that of xenobiotic metabolism. Reports provide evidence for the involvement of AHR in immune function from both toxicological and physiological perspectives. AHR ligands alter embryonic immune development and programming (Hogaboam et al., 2008) ; induce thymic atrophy in rodents through enhanced FasLmediated apoptosis (Camacho et al., 2005; Kamath et al., 1997) ; diminish B-lymphopoiesis (Schneider et al., 2008) and the B-cell IgM response (North et al., 2009) , and promote the polarization of T H 1/2 cells, generating a T H 1 bias (Negishi et al., 2005) . Recently, focus has turned to the role of the AHR in facilitating the differentiation of CD4+ lymphocytes into T H 17 and T Reg cells. The T H 17 population is sub-optimal in the presence of an AHR antagonist (Veldhoen et al., 2009) with the implication that endogenous AHR ligands stimulate T H 17 commitment. Furthermore, Ahr knockout models exhibit attenuated T H 17 differentiation, substantiating AHR involvement (Kimura et al., 2008) . Despite the diversity of immunological effects prompted by the AHR, little is known regarding a mode of action, but it is likely to involve cross-talk mechanisms. Notwithstanding, the immune-suppressive activity exhibited by the AHR raises the question-can the AHR represent a novel drug target for the treatment of inflammatory or autoimmune conditions?
Recently, an established in vivo model of multiple sclerosis, experimental acute encephalitis (EAE) has been shown to be ameliorated by the prototypical AHR agonist 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) and yet, be enhanced by FICZ, also an AHR ligand (Quintana et al., 2008; Veldhoen et al., 2008) . Additionally, non-obese diabetic (NOD) mice predisposed to autoimmune diabetes fail to develop This article has not been copyedited and formatted. The final version may differ from this version. (Kerkvliet, 2009) . Both are suspected to involve reprogramming of T cells. Whilst illustrating the involvement of AHR, the use of polycyclic hydrocarbon agonists is not therapeutically viable due to the perceived inherent toxicity associated with AHR activation. Indeed, the AHR has a dubious reputation as a mediator of various modes of toxicity, including the conversion of procarcinogens into genotoxic intermediates through enhanced phase I bioactivity (Sagredo et al., 2006) .
Deleterious effects result from ligand-activated AHR in combination with its dimerization partner ARNT binding to DREs within AHR target genes, thus facilitating the expression of downstream effectors. We hypothesize that a selective AHR ligand with the capacity to promote dissociation between the beneficial cross-talk modes of AHR action away from its DRE-dependent toxic activity could render the AHR a viable therapeutic target.
This hypothesis of ligand-dependent but DRE-independent AHR activity has been tested utilizing a DNAbinding AHR mutant, identifying numerous genes which were suppressed in response to ligand (Patel et al., 2009) . Predominant among these were components of the inflammatory acute phase response (APR), e.g. serum amyloid-associated (Saa1) and C-reactive protein (Crp). These targets emphasized the involvement of AHR in the modulation of inflammatory signaling and established a subset of targets to screen and validate potential selective AHR modulators (SAhRMs) i.e. AHR ligands with the capacity to promote DNA-independent AHR activity at the expense of DRE-mediated expression. The concept of selective receptor modulators is well established for nuclear hormone receptors, especially within the context of the estrogen receptor, and has been utilized clinically in the treatment of hormone-sensitive cancer. The selective modulator concept has expanded to include other nuclear receptors, however, the idea and therapeutic viability of SAhRMs has not been expounded.
In line with its function as a xenobiotic sensor, the AHR is remarkably promiscuous, binding diverse ligands, including some ER ligands e.g. resveratrol, which antagonize canonical AHR signaling (Casper et al., 1999) . Like TCDD, resveratrol ameliorates EAE by impacting T cell function (Singh et al., 2007) . This article has not been copyedited and formatted. The final version may differ from this version. Harnish et al., 2006) , thus presenting a potential for Way-169916 to influence the DNA-independent repressive action of AHR. We investigated this hypothesis and present evidence that Way-169916 is an AHR ligand and represents the first report of a SAhRM with anti-inflammatory properties.
This article has not been copyedited and formatted. The final version may differ from this version. Chemical synthesis. 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1, 3-diol (Way-169916) was synthesized as previously described with minor modifications (Steffan et al., 2004) . Comprehensive methods and synthesis scheme are detailed in supplemental information. The structure and purity of Way-169916 were verified by ESI-MS and N.M.R.
Cell culture. The human hepatoma Huh7 cell line was maintained in α-minimal essential medium (α-MEM) (Sigma, St. Louis, MO) supplemented with 8% fetal bovine serum (Hyclone Labs, Logan, UT), 100 IU/ml penicillin and 100 μg/ml streptomycin (Sigma). Cells were cultured at 37°C in a humidified atmosphere comprised of 95% air and 5% CO 2 .
Electromobility shift assay. DRE-specific electrophoretic mobility shift assays (EMSA) were performed using in vitro translated human AHR and ARNT proteins. Expression vectors for each protein were translated separately using the T7 TNT kit (Promega Corp., Madison, WI), reactions were modified to include 1.25 mM sodium molybdate to enhance AHR stability. Aliquots (4μl) of AHR and ARNT were combined at a 1:1 molar ratio in HEDG (25 mM HEPES, 1 mM EDTA, 10 mM sodium molybdate and 10% glycerol, pH 7.5) buffer, followed by the addition of 0.25 μl ligand or vehicle, for a total reaction volume equaling 10 μl. Transformation reactions were incubated for 90 min at room temperature, followed by the addition of 15 μl of oligonucleotide binding buffer (42 mM Hepes, 0.33 M KCl, 50% This article has not been copyedited and formatted. The final version may differ from this version. Competitive AHR ligand binding assay. Competitive ligand binding assays were performed as previously described . Briefly, The AHR photoaffinity ligand; 2-azido-3-[ 125 I]iodo-7, 8-dibromodibenzo-p-dioxin (PAL) was synthesized as described previously (Poland et al., 1986) .
Hepatic cytosol extracts were isolated from B6.Cg-Ahr tm3.1 Bra Tg (Alb-cre, Ttr-AHR)1GHP "humanized" AHR mice RNA isolation and reverse transcription. Total RNA was isolated from Huh7 cells cultured in six-well plates using Trizol (Invitrogen). RNA concentration was determined via spectrophotometry at λ 260 nm This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 3A) . In contrast, Way-169916 failed to elicit a significant induction of CYP1A1
This article has not been copyedited and formatted. The final version may differ from this version. Fig. 2.) . Further examination using HepG2 cells stably integrated with a CYP1A1 enhancer-luciferase reporter construct revealed that the failure of Way-169916 to induce AHR dependent gene expression was not associated with dose or temporal issues (Fig. 3B) . Although a modest increase in reporter activity was observed with Way-169916 at 3 h, this proved not to be statistically significant, suggesting very weak agonist activity. We also examined the capacity of Way-169916 to antagonize TCDD-mediated expression of an AHR-dependent reporter construct. HepG2 (40/6) cells harboring the DRE-driven pGudluc 6.1 reporter were exposed to vehicle, TCDD, or in combination with increasing concentrations of Way-169916, and reporter expression was assayed. Exposure to TCDD prompted a robust induction of reporter activity, which was significantly repressed upon co-exposure to Way-169916 (Fig. 4. ). These data in conjunction with our ligand-binding data indicate that Way-169916 is an extremely weak agonist with the capacity to be an effective competitive antagonist with regard to canonical DRE-dependent AHR transactivation. (Fig. 5.) . Furthermore, exposure of Huh7 cells to increasing concentrations of Way-169916 identified a dose-dependent suppression of cytokine-mediated APR expression (Fig. 5B.) .
Way
Attenuation of APR gene expression by Way-169916 is independent of ER. Way-169916 was
originally developed as a SERM and has been shown to repress gene expression in rodent models of inflammation by a mechanism involving the estrogen receptor . Using a fluorescent polarization competition assay we were able to confirm the status of Way-169916 as a ligand for ER (Fig. 6A) . Thus, despite being a ligand for AHR, our data illustrating attenuation of APR gene expression could be attributed to the SERM nature of Way-169916. We examined this scenario by co- 
Suppression of APR expression by Way-169916 is AHR-dependent. Having established that Way-
169916 is an AHR ligand with the capacity to repress the cytokine-mediated expression of acute phase reaction components independently of ER, we wished to investigate if the AHR/ARNT complex is a requirement for repression. Previous data indicated APR repression following exposure to AHR antagonists thus rendering them unsuitable for AHR inhibition in this context (Patel et al., 2009 repression of APR expression. We therefore used a double knockdown approach; using siRNA targeted against AHR and its obligatory dimerization partner ARNT. Huh7 cells transfected with a non-targeting scrambled siRNA oligonucleotide were sensitive to Way-169916-mediated repression of SAA1 (Fig.7.) .
By contrast, cells with diminished protein expression of AHR and ARNT arising from transfection with siRNA oligonucleotides targeted against AHR and ARNT were refractory to Way-169916 and demonstrated no significant repression of SAA1 (Fig. 7B.) . These data indicate that the AHR/ARNT complex is necessary and sufficient to mediate Way-169916-mediated APR repression. 
Way
Discussion.
The clinical application of SERMs has been a reality for many years, even pre-dating the evolution of the SERM concept. It was the seminal observation that nuclear hormone receptors, particularly the steroid receptors, e.g. estrogen and glucocorticoid receptors, exhibit the phenomenon of DNA-independent transrepression and are not restricted solely to direct gene activation events through their cognate response elements and thus identified the physiological essence for selectivity (Reichardt et al., 1998) .
Whilst evolutionarily and structurally dissimilar to the steroid nuclear hormone receptor family, the aryl hydrocarbon receptor (AHR), the only known ligand-activated member of the basic helix-loop-helix/PAS family of transcription factors behaves in an analogous fashion to elicit gene induction (Beischlag et al., 2008) . Binding of an agonist e.g. TCDD, increases the affinity of AHR for its cognate response element and facilitates the expression of AHR-responsive genes, principally members of the CYP1 P450 family, often leading to genotoxic stress or endocrine disruption (Safe, 1995; Sagredo et al., 2006) . Despite the functional similarity between AHR and the nuclear receptor family, the notion of therapeutic modulation of AHR has, with the notable exception of its ability to antagonize ER function and mitigate hormonesensitive tumor growth, largely been overlooked (Safe and McDougal, 2002) . However, numerous recent reports have demonstrated the integration of the AHR into signaling pathways not directly connected with xenobiotic metabolism. Activation of AHR with putative endogenous ligands has been shown to exert profound effects upon the immune system, suggesting a physiological role for AHR (Stevens et al., 2009 ).
The association between AHR and the immune system, whilst known for a number of years from a toxicological immunosuppressive perspective (Kerkvliet, 2002) , is only now being considered for its potential therapeutic applications in the treatment of autoimmune or inflammatory disease (Kerkvliet, 2009; Quintana et al., 2008; Veldhoen et al., 2008) . Currently, the highly characterized role of AHR in mediating various aspects of toxicity has been a major obstacle in realizing the latent therapeutic (Bhat and Pezzuto, 2001; Casper et al., 1999) . Interestingly, resveratrol exhibits antagonistic activity for both ER and AHR. We therefore investigated the ability of Way-169916 to promote AHR transformation, DRE binding and stimulate AHR-dependent gene expression. Way-169916 proved to be a very weak partial AHR agonist in the context of both endogenous CYP1A1 mRNA expression and heterologous DRE-reporter activity. This weak activity can be attributed to greatly diminished association between AHR and its response element relative to typical AHR agonists. At this time, it is unclear whether Way-169916 is inefficient at inducing AHR transformation from the chaperone-bound complex into its heterodimeric 6S conformation and/or influences AHR structurally to directly diminish DRE affinity. In its capacity as a SERM, Way-169916 could influence DRE-dependent gene expression through the documented cross-talk of ER and AHR (Matthews and Gustafsson, 2006) .
This scenario was eliminated in the context of our Huh7-based expression analyses due to the absence of ERα and ERβ expression in this cell line, but emphasizes a requirement to fully characterize putative SAhRMs due to the frequent overlap between AHR and ER with regard to ligands, modes of activation, repression and mutual antagonism.
The revelation that Way-169916 binds AHR yet invokes minimal canonical DRE-driven AHR signaling and is thus unlikely to promote subsequent AHR toxicities fulfills one of the major criteria of a putative SAhRM. Indeed, previous in vivo gene profiling analyses in multiple tissues did not highlight the induction of any characteristic DRE-driven AHR targets in response to Way-169916 .
The second defining facet of SAhRM activity is demonstrated with the repression of inflammatory APR gene targets by Way-169916. Anti-inflammatory action by Way-169916 is reported in various rodent models of inflammation, including rheumatoid arthritis, chronic intestinal inflammation, and ischemiareperfusion injury, which highlights an ER-dependent suppression of NF-κB activity to account for diminished APR expression (Booth et al., 2007; Chadwick et al., 2005; Harnish et al., 2006) . Whilst this mechanism of action is valid, it fails to explain the observed repression in Huh7 cells which lack ER expression. Previous data using the DNA-binding AHR mutant, various structurally diverse AHR ligands, and the observation that Way-169916 is an AHR ligand, all support our contention that repression of APR targets can occur through AHR independently of ER. Although different experimental approaches were employed, it is interesting to note that despite having a much lower affinity for AHR, the Way-169916-mediated reduction in APR expression reported here is similar to that obtained through the ER-dependent mechanism .
As proof of the SAhRM concept, an examination of the mechanism behind the AHR-dependent APR repression is beyond the scope of this manuscript. It is plausible that inhibition through AHR cross-talk is the underlying cause of repression. Such cross-talk between AHR and inflammatory mediators is not without precedent. Indeed, many of the toxic immunosuppressive outcomes attributed to sustained AHR This article has not been copyedited and formatted. The final version may differ from this version. 18 activation by environmental contaminants are thought to involve cross-talk signaling (Tian et al., 2002) .
Studies showing APR repression with TCDD indicate a requirement for AHR translocation into the nucleus, as an AHR mutant deficient in translocation failed to mediate repression, thus eliminating a mechanism involving the AHR-mediated nuclear blockade of a necessary regulator (Patel et al., 2009) .
Furthermore, heterodimerization is also a prerequisite for AHR-mediated APR repression, as evidenced by AHR mutants lacking affinity for ARNT. We are currently investigating the molecular basis for
SAhRM activity with the aim of identifying novel SAhRMs that exhibit enhanced efficacy and selectivity.
In conclusion, it is our contention that the anti-inflammatory non-steroidal SERM Way-169916 also exhibits affinity for the AHR and in doing so retains anti-inflammatory characteristics with regard to APR expression. Furthermore, the AHR-mediated anti-inflammatory activity occurs in the absence of potentially toxic canonical DRE-dependent gene expression. As such, Way-169916 represents the first example of a selective AHR modulator. Importantly, these data lend credence to the SAhRM concept and support the notion that the AHR represents a viable therapeutic target for the treatment of inflammatory disorders.
This article has not been copyedited and formatted. The final version may differ from this version. 
